CGON vs. RAPT

Last updated Apr 1, 2026

Compare and contrast key facts about CG Oncology, Inc (CGON) and RAPT Therapeutics, Inc. (RAPT).

Performance

CGON vs. RAPT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CG Oncology, Inc (CGON) and RAPT Therapeutics, Inc. (RAPT). The values are adjusted to include any dividend payments, if applicable.

CGON vs. RAPT - Yearly Performance Comparison

	2026 (YTD)	2025	2024
CGON CG Oncology, Inc	63.01%	44.77%	-22.84%
RAPT RAPT Therapeutics, Inc.	71.30%	167.96%	-93.40%

Fundamentals

Market Cap CGON : $5.23B RAPT : $1.56B
EPS CGON : -$2.10 RAPT : -$3.92
PB Ratio CGON : 6.95 RAPT : 10.29
Total Revenue (TTM) CGON : $4.04M RAPT : $0.00
Gross Profit (TTM) CGON : -$607.00K RAPT : -$200.00K
EBITDA (TTM) CGON : -$167.30M RAPT : -$108.01M

Returns By Period

In the year-to-date period, CGON achieves a 63.01% return, which is significantly lower than RAPT's 71.30% return.

CGON

• 1D: 5.82%
• 1M: 15.10%
• YTD: 63.01%
• 6M: 68.02%
• 1Y: 176.36%
• 3Y*: —
• 5Y*: —
• 10Y*: —

RAPT

• 1D: 0.00%
• 1M: 0.07%
• YTD: 71.30%
• 6M: 124.97%
• 1Y: 494.47%
• 3Y*: -38.25%
• 5Y*: -15.58%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CGON vs. RAPT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CGON

CGON Risk / Return Rank: 92
CGON Sharpe Ratio Rank: 94
CGON Sortino Ratio Rank: 91
CGON Omega Ratio Rank: 91
CGON Calmar Ratio Rank: 91
CGON Martin Ratio Rank: 94

RAPT

RAPT Risk / Return Rank: 98
RAPT Sharpe Ratio Rank: 99
RAPT Sortino Ratio Rank: 98
RAPT Omega Ratio Rank: 97
RAPT Calmar Ratio Rank: 99
RAPT Martin Ratio Rank: 98

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CGON vs. RAPT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CG Oncology, Inc (CGON) and RAPT Therapeutics, Inc. (RAPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CGON	RAPT	Difference
Sharpe ratio Return per unit of total volatility	2.50	4.73	-2.23
Sortino ratio Return per unit of downside risk	3.00	4.47	-1.47
Omega ratio Gain probability vs. loss probability	1.42	1.59	-0.17
Calmar ratio Return relative to maximum drawdown	4.30	11.35	-7.05
Martin ratio Return relative to average drawdown	15.60	25.83	-10.23
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CGON vs. RAPT - Sharpe Ratio Comparison

The current CGON Sharpe Ratio is 2.50, which is lower than the RAPT Sharpe Ratio of 4.73. The chart below compares the historical Sharpe Ratios of CGON and RAPT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CGON	RAPT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.50	4.73	-2.23
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.13	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.49	-0.07	+0.56

Correlation

The correlation between CGON and RAPT is 0.33, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CGON vs. RAPT - Dividend Comparison

Neither CGON nor RAPT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CGON vs. RAPT - Drawdown Comparison

The maximum CGON drawdown since its inception was -67.47%, smaller than the maximum RAPT drawdown of -98.47%. Use the drawdown chart below to compare losses from any high point for CGON and RAPT.

Drawdown Indicators

	CGON	RAPT	Difference
Max Drawdown Largest peak-to-trough decline	-67.47%	-98.47%	+31.00%
Max Drawdown (1Y) Largest decline over 1 year	-29.90%	-36.08%	+6.18%
Max Drawdown (5Y) Largest decline over 5 years	—	-98.14%	—
Current Drawdown Current decline from peak	-1.40%	-85.16%	+83.76%
Average Drawdown Average peak-to-trough decline	-27.36%	-63.85%	+36.49%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.01%	22.87%	-12.86%

Volatility

CGON vs. RAPT - Volatility Comparison

CG Oncology, Inc (CGON) has a higher volatility of 13.55% compared to RAPT Therapeutics, Inc. (RAPT) at 0.51%. This indicates that CGON's price experiences larger fluctuations and is considered to be riskier than RAPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CGON	RAPT	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.55%	0.51%	+13.04%
Volatility (6M) Calculated over the trailing 6-month period	42.77%	69.27%	-26.50%
Volatility (1Y) Calculated over the trailing 1-year period	71.55%	119.45%	-47.90%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	65.29%	123.30%	-58.01%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	65.29%	124.92%	-59.63%

Financials